



July 30, 2013
AnGes MG, Inc.

AnGes and Tella Sign Basic Agreement for Joint Research and Development of CIN Therapeutic Vaccine

AnGes MG, Inc. (“AnGes”) announced today that it has signed a basic agreement for joint research and development of a cervical intraepithelial neoplasia (CIN) therapeutic vaccine with Tella, Inc. (Chiyoda-ku, Tokyo, President & Representative Director: Yuichiro Yazaki, “Tella”). Under the agreement, AnGes and Tella will pursue joint research and development to realize practical application of a CIN therapeutic vaccine.

Human papilloma virus (HPV), which causes cervical cancer, is detected from an early stage as a precancerous lesion. Expression of HPV oncoproteins, especially E7, increase as it progresses into CIN, and contributes to the development of cervical cancer. The CIN therapeutic vaccine of AnGes induces mucosal HPV E7 antigen-specific cellular immune response on neoplastic lesions and could cause CIN3 (the late stage of CIN) lesions to disappear. It is expected to be an innovative world’s first orally administrable therapeutic vaccine for preventing the development of cervical cancer.

In cervical cancer, the peak age of those who progress from precancerous lesions to intraepithelial neoplasia is around 30 years old. This is an age group that commonly experiences marriage and childbirth. It has been reported that there are increased risks of premature delivery, low birth weight, and caesarean section among those who have undergone conization of the cervix. Thus, prevention of cervical conization is of great significance and early realization of this therapeutic vaccine is desired.

AnGes has been undertaking the development of a CIN therapeutic vaccine, and Tella has strength for developing cancer immunotherapies. Tella has experience in providing 29 national medical institutions and university hospitals with its cancer treatment technologies and expertise in dendritic cell vaccine therapy, a cancer immunotherapy.

Under the agreement, the 2 companies aim to effectively enforce the development of treatments against precancerous conditions of the cervix by combing AnGes’ CIN therapeutic vaccine with Tella’s cutting-edge technologies and expertise on a dendritic cell

vaccine. Furthermore, the 2 companies will consider the possibility of developing other treatment options in the area.

This trend will have no effect on business performance for the fiscal year 2013.

AnGes MG, Inc.

Address: 4F, Saito Bio-Incubator, 7-7-15, Saito-asagi, Ibaraki, Osaka, 567-0085 Japan

President and CEO: Ei Yamada

Established: December 17, 1999

Scope of business: Research and development of genetic medicine

Tella, Inc.

Address: Sunline 7th Bldg 7th Floor, 4-7-2 Kojimachi, Chiyoda-ku, Tokyo. 102-0083, Japan

President and Representative Director: Yuichiro Yazaki

Established: June 24, 2004

Scope of business:

- Provision of technical and operational expertise associated with cellular medicines, including dendritic cell vaccine therapy, to affiliated medical institutions.
- Research and development of regenerative medicines and cellular medicines, including dendritic cell vaccine therapy.

###

Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.

<p>AnGes MG, Inc. Corporate Communications TEL: +81-3-5730-2641, FAX: +81-3-5730-2635 http://www.anges-mg.com</p>
